ELVUCITABINE is a HIV nucleoside for the $3.7B NRTI market that has demonstrated potent antiviral activity, including against HIV strains resistant to other NRTIs.

ACH-702 is a
broad-spectrum bactericidal orally available compound for $2B serious bacterial infections market with a novel target profile against bacterial DNA replication enzymes.

ACH-1095 is a novel-mechanism NS4A antagonist being developed by Achillion and Gilead for the $4B HCV market.

PROTEASE INHIBITORS are potent inhibitors of HCV NS3 protease with good early toxicology and PK profiles and potential for once-daily dosing.